Failed Experiment ReportOpen accessMedicine· cited by 19

Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

Maria Fortunata Lofiego; Francesca Piazzini; Francesca Pia Caruso; Francesco Marzani; Laura Solmonese; Emma Bello; Fabrizio Celesti; Maria Claudia Costa · 2024 · Journal of Translational Medicine

WASTE classifies this as Failed Experiment Report · AI classification, approximate

An experimental approach did not work as intended — learn what to avoid before investing the same effort.

Abstract

BACKGROUND: Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor, that is refractory to standard treatment and to immunotherapy with immune-checkpoint inhibitors (ICI). Noteworthy, melanoma brain metastases (MM-BM), that share the same niche as GBM, frequently respond to current ICI therapies. Epigenetic modifications regulate GBM cellular proliferation, invasion, and prognosis and may negatively regulate the cross-talk between malignant cells and immune cells in the tumor milieu, likely contributing to limit the efficacy of ICI therapy of GBM. Thus, manipulating the tumor

Abstract by Maria Fortunata Lofiego; Francesca Piazzini; Francesca Pia Caruso; Francesco Marzani; Laura Solmonese; Emma Bello; Fabrizio Celesti; Maria Claudia Costa, Journal of Translational Medicine (2024) — licensed CC BY 4.0.

Read the full paper (open access)